ARTICLE | Clinical News
Ecopipam: Phase IIb ongoing
February 8, 2016 8:00 AM UTC
Psyadon said an independent DSMB recommended continuation of the double-blind, crossover, U.S. Phase IIb PSY302 trial evaluating 50 and 100 mg ecopipam once daily based on an interim data review of 15...